Amgen Q1 2026 Revenue Beats Estimates, EPS Tops Consensus
Biotech company Amgen (NASDAQ:AMGN) reported Q1 CY2026 results exceeding revenue expectations, with sales up 5.8% year on year to $8.62 billion. Non-GAAP profit of $5.15 per share was 8% above analysts' consensus estimates. The company expects full-year revenue around $37.8 billion, close to estimates.
Key Numbers
Biotech company Amgen (NASDAQ:AMGN) reported Q1 CY2026 results exceeding market revenue expectations. Revenue came in at $8.62 billion, up 5.8% year over year. Non-GAAP earnings per share of $5.15 beat analysts' consensus by 8%.
Key Financial Results
| Metric | Value | YoY Change |
|---|---|---|
| Revenue | $8.62B | +5.8% |
| Non-GAAP EPS | $5.15 | +8% vs consensus |
| Full-year revenue guidance | ~$37.8B | Near estimates |
Highlights from the Release
Amgen attributed revenue growth to strong performance across its key product portfolio, particularly in oncology and inflammation. No further details on specific growth drivers were provided.
Guidance
Amgen guided full-year 2026 revenue to approximately $37.8 billion, close to analyst estimates, indicating management confidence in sustained momentum.
Stock Impact
Immediate stock reaction was not reported. However, beating estimates typically supports short-term positive performance.
What This Means for Investors
Amgen's Q1 results demonstrate its ability to grow in a competitive environment. Revenue and earnings beats reflect solid execution. Investors should monitor full-year guidance to assess growth sustainability.
Frequently Asked Questions
Found this useful? Share it